Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
1,761
archived clinical trials in
Osteoporosis

Study of Romosozumab (AMG 785) Administered to Healthy Participants and Patients With Stage 4 Renal Impairment or Stage 5 Renal Impairment Requiring Hemodialysis
A Phase 1, Open-label, Single-dose Study of Romosozumab (AMG 785) Administered Subcutaneously to Healthy Subjects and Subjects With Stage 4 Renal Impairment or Stage 5 Renal Impairment Requiring Hemodialysis
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Pembroke Pines, FL
Study of Romosozumab (AMG 785) Administered to Healthy Participants and Patients With Stage 4 Renal Impairment or Stage 5 Renal Impairment Requiring Hemodialysis
A Phase 1, Open-label, Single-dose Study of Romosozumab (AMG 785) Administered Subcutaneously to Healthy Subjects and Subjects With Stage 4 Renal Impairment or Stage 5 Renal Impairment Requiring Hemodialysis
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Pembroke Pines, FL
Click here to add this to my saved trials
Study of Romosozumab (AMG 785) Administered to Healthy Participants and Patients With Stage 4 Renal Impairment or Stage 5 Renal Impairment Requiring Hemodialysis
A Phase 1, Open-label, Single-dose Study of Romosozumab (AMG 785) Administered Subcutaneously to Healthy Subjects and Subjects With Stage 4 Renal Impairment or Stage 5 Renal Impairment Requiring Hemodialysis
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Orangeburg, SC
Study of Romosozumab (AMG 785) Administered to Healthy Participants and Patients With Stage 4 Renal Impairment or Stage 5 Renal Impairment Requiring Hemodialysis
A Phase 1, Open-label, Single-dose Study of Romosozumab (AMG 785) Administered Subcutaneously to Healthy Subjects and Subjects With Stage 4 Renal Impairment or Stage 5 Renal Impairment Requiring Hemodialysis
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Orangeburg, SC
Click here to add this to my saved trials
Study of Romosozumab (AMG 785) Administered to Healthy Participants and Patients With Stage 4 Renal Impairment or Stage 5 Renal Impairment Requiring Hemodialysis
A Phase 1, Open-label, Single-dose Study of Romosozumab (AMG 785) Administered Subcutaneously to Healthy Subjects and Subjects With Stage 4 Renal Impairment or Stage 5 Renal Impairment Requiring Hemodialysis
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Los Angeles, CA
Study of Romosozumab (AMG 785) Administered to Healthy Participants and Patients With Stage 4 Renal Impairment or Stage 5 Renal Impairment Requiring Hemodialysis
A Phase 1, Open-label, Single-dose Study of Romosozumab (AMG 785) Administered Subcutaneously to Healthy Subjects and Subjects With Stage 4 Renal Impairment or Stage 5 Renal Impairment Requiring Hemodialysis
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Melatonin-Micronutrients for Osteopenia Treatment Study
Phase 1 Study of Combination Strontium, Melatonin and Nutritional Co-factors on Bone Health and Quality of Life in Postmenopausal Women With Osteopenia
Status: Enrolling
Updated:  12/31/1969
Duquesne University Center for Pharmacy Care
mi
from
Pittsburgh, PA
Melatonin-Micronutrients for Osteopenia Treatment Study
Phase 1 Study of Combination Strontium, Melatonin and Nutritional Co-factors on Bone Health and Quality of Life in Postmenopausal Women With Osteopenia
Status: Enrolling
Updated: 12/31/1969
Duquesne University Center for Pharmacy Care
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
A Randomized Phase 3 Study to Evaluate Two Formulations of Romosozumab in Postmenopausal Women With Osteoporosis
A Multicenter, Randomized, Multiple-dose Phase 3 Study to Evaluate the Noninferiority of Romosozumab at a 90 mg/mL Concentration Compared With a 70 mg/mL Concentration in Postmenopausal Women With Osteoporosis
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Gainesville, GA
A Randomized Phase 3 Study to Evaluate Two Formulations of Romosozumab in Postmenopausal Women With Osteoporosis
A Multicenter, Randomized, Multiple-dose Phase 3 Study to Evaluate the Noninferiority of Romosozumab at a 90 mg/mL Concentration Compared With a 70 mg/mL Concentration in Postmenopausal Women With Osteoporosis
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Gainesville, GA
Click here to add this to my saved trials
A Randomized Phase 3 Study to Evaluate Two Formulations of Romosozumab in Postmenopausal Women With Osteoporosis
A Multicenter, Randomized, Multiple-dose Phase 3 Study to Evaluate the Noninferiority of Romosozumab at a 90 mg/mL Concentration Compared With a 70 mg/mL Concentration in Postmenopausal Women With Osteoporosis
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Bethesda, MD
A Randomized Phase 3 Study to Evaluate Two Formulations of Romosozumab in Postmenopausal Women With Osteoporosis
A Multicenter, Randomized, Multiple-dose Phase 3 Study to Evaluate the Noninferiority of Romosozumab at a 90 mg/mL Concentration Compared With a 70 mg/mL Concentration in Postmenopausal Women With Osteoporosis
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Bethesda, MD
Click here to add this to my saved trials
A Randomized Phase 3 Study to Evaluate Two Formulations of Romosozumab in Postmenopausal Women With Osteoporosis
A Multicenter, Randomized, Multiple-dose Phase 3 Study to Evaluate the Noninferiority of Romosozumab at a 90 mg/mL Concentration Compared With a 70 mg/mL Concentration in Postmenopausal Women With Osteoporosis
Status: Enrolling
Updated:  12/31/1969
Investigator Site 102
mi
from
Brno,
A Randomized Phase 3 Study to Evaluate Two Formulations of Romosozumab in Postmenopausal Women With Osteoporosis
A Multicenter, Randomized, Multiple-dose Phase 3 Study to Evaluate the Noninferiority of Romosozumab at a 90 mg/mL Concentration Compared With a 70 mg/mL Concentration in Postmenopausal Women With Osteoporosis
Status: Enrolling
Updated: 12/31/1969
Investigator Site 102
mi
from
Brno,
Click here to add this to my saved trials
Denosumab for Prevention of Post-Teriparatide Bone Loss in Premenopausal Women With IOP
Denosumab for Prevention of Post-Teriparatide Bone Loss in Premenopausal Women With Idiopathic Osteoporosis (IOP)
Status: Enrolling
Updated:  12/31/1969
Creighton University
mi
from
Omaha, NE
Denosumab for Prevention of Post-Teriparatide Bone Loss in Premenopausal Women With IOP
Denosumab for Prevention of Post-Teriparatide Bone Loss in Premenopausal Women With Idiopathic Osteoporosis (IOP)
Status: Enrolling
Updated: 12/31/1969
Creighton University
mi
from
Omaha, NE
Click here to add this to my saved trials
Denosumab for Prevention of Post-Teriparatide Bone Loss in Premenopausal Women With IOP
Denosumab for Prevention of Post-Teriparatide Bone Loss in Premenopausal Women With Idiopathic Osteoporosis (IOP)
Status: Enrolling
Updated:  12/31/1969
Columbia University Medical Center
mi
from
New York, NY
Denosumab for Prevention of Post-Teriparatide Bone Loss in Premenopausal Women With IOP
Denosumab for Prevention of Post-Teriparatide Bone Loss in Premenopausal Women With Idiopathic Osteoporosis (IOP)
Status: Enrolling
Updated: 12/31/1969
Columbia University Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
Bone, Endocrine and Lifestyle Longitudinal Study
Bone, Endocrine and Lifestyle Longitudinal Study
Status: Enrolling
Updated:  12/31/1969
Women's Health and Exercise Laboratory, University of southern California
mi
from
Los Angeles, CA
Bone, Endocrine and Lifestyle Longitudinal Study
Bone, Endocrine and Lifestyle Longitudinal Study
Status: Enrolling
Updated: 12/31/1969
Women's Health and Exercise Laboratory, University of southern California
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Bone Disease in Chronic Pancreatitis: A Complex Phenomenon
Bone Disease in Chronic Pancreatitis: A Complex Phenomenon
Status: Enrolling
Updated:  12/31/1969
Univ of Nebraska Med Ctr
mi
from
Omaha, NE
Bone Disease in Chronic Pancreatitis: A Complex Phenomenon
Bone Disease in Chronic Pancreatitis: A Complex Phenomenon
Status: Enrolling
Updated: 12/31/1969
Univ of Nebraska Med Ctr
mi
from
Omaha, NE
Click here to add this to my saved trials
A Study of Blosozumab (LY2541546) in Postmenopausal Female Participants
A Multiple Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Blosozumab Proposed Phase 3 Formulation in Postmenopausal Women
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Daytona Beach, FL
A Study of Blosozumab (LY2541546) in Postmenopausal Female Participants
A Multiple Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Blosozumab Proposed Phase 3 Formulation in Postmenopausal Women
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Daytona Beach, FL
Click here to add this to my saved trials
A Study of Blosozumab (LY2541546) in Postmenopausal Female Participants
A Multiple Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Blosozumab Proposed Phase 3 Formulation in Postmenopausal Women
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Dallas, TX
A Study of Blosozumab (LY2541546) in Postmenopausal Female Participants
A Multiple Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Blosozumab Proposed Phase 3 Formulation in Postmenopausal Women
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
Tocotrienols and Bone Health of Postmenopausal Women
Effect of Tocotrienols on Bone Health: A Pilot Study
Status: Enrolling
Updated:  12/31/1969
Texas Tech University Health Sciences Center
mi
from
Lubbock, TX
Tocotrienols and Bone Health of Postmenopausal Women
Effect of Tocotrienols on Bone Health: A Pilot Study
Status: Enrolling
Updated: 12/31/1969
Texas Tech University Health Sciences Center
mi
from
Lubbock, TX
Click here to add this to my saved trials
Bone Health in Youth With Type 1 Diabetes
Bone Mineral Accrual and Microarchitecture in Youth With Type 1 Diabetes
Status: Enrolling
Updated:  12/31/1969
Massachusetts General Hospital
mi
from
Boston, MA
Bone Health in Youth With Type 1 Diabetes
Bone Mineral Accrual and Microarchitecture in Youth With Type 1 Diabetes
Status: Enrolling
Updated: 12/31/1969
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Pathogenesis of Atypical Femur Fractures on Long Term Bisphosphonate Therapy
Pathogenesis of Atypical Femur Fractures on Long Term Bisphosphonate Therapy
Status: Enrolling
Updated:  12/31/1969
Henry Ford Medical Center, New Center One
mi
from
Detroit, MI
Pathogenesis of Atypical Femur Fractures on Long Term Bisphosphonate Therapy
Pathogenesis of Atypical Femur Fractures on Long Term Bisphosphonate Therapy
Status: Enrolling
Updated: 12/31/1969
Henry Ford Medical Center, New Center One
mi
from
Detroit, MI
Click here to add this to my saved trials
Denosumab and Teriparatide Study (DATA-HD and DATA-EX)
Denosumab and Teriparatide Study (DATA-HD and DATA-EX)
Status: Enrolling
Updated:  12/31/1969
Massachusetts General Hospital
mi
from
Boston, MA
Denosumab and Teriparatide Study (DATA-HD and DATA-EX)
Denosumab and Teriparatide Study (DATA-HD and DATA-EX)
Status: Enrolling
Updated: 12/31/1969
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
A Double-blind Study to Compare the Safety and Efficacy of Romosozumab (AMG 785) Versus Placebo in Men With Osteoporosis
A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Compare the Efficacy and Safety of Romosozumab (AMG 785) With Placebo in Men With Osteoporosis
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Lakewood, CO
A Double-blind Study to Compare the Safety and Efficacy of Romosozumab (AMG 785) Versus Placebo in Men With Osteoporosis
A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Compare the Efficacy and Safety of Romosozumab (AMG 785) With Placebo in Men With Osteoporosis
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Lakewood, CO
Click here to add this to my saved trials
A Double-blind Study to Compare the Safety and Efficacy of Romosozumab (AMG 785) Versus Placebo in Men With Osteoporosis
A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Compare the Efficacy and Safety of Romosozumab (AMG 785) With Placebo in Men With Osteoporosis
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Bethesda, MD
A Double-blind Study to Compare the Safety and Efficacy of Romosozumab (AMG 785) Versus Placebo in Men With Osteoporosis
A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Compare the Efficacy and Safety of Romosozumab (AMG 785) With Placebo in Men With Osteoporosis
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Bethesda, MD
Click here to add this to my saved trials
A Double-blind Study to Compare the Safety and Efficacy of Romosozumab (AMG 785) Versus Placebo in Men With Osteoporosis
A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Compare the Efficacy and Safety of Romosozumab (AMG 785) With Placebo in Men With Osteoporosis
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Albuquerque, NM
A Double-blind Study to Compare the Safety and Efficacy of Romosozumab (AMG 785) Versus Placebo in Men With Osteoporosis
A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Compare the Efficacy and Safety of Romosozumab (AMG 785) With Placebo in Men With Osteoporosis
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Albuquerque, NM
Click here to add this to my saved trials
A Double-blind Study to Compare the Safety and Efficacy of Romosozumab (AMG 785) Versus Placebo in Men With Osteoporosis
A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Compare the Efficacy and Safety of Romosozumab (AMG 785) With Placebo in Men With Osteoporosis
Status: Enrolling
Updated:  12/31/1969
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
mi
from
Genk,
A Double-blind Study to Compare the Safety and Efficacy of Romosozumab (AMG 785) Versus Placebo in Men With Osteoporosis
A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Compare the Efficacy and Safety of Romosozumab (AMG 785) With Placebo in Men With Osteoporosis
Status: Enrolling
Updated: 12/31/1969
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
mi
from
Genk,
Click here to add this to my saved trials
Heartland Osteoporosis Prevention Study
Randomized Control Trial of Bone Loading Exercises Versus Risedronate on Bone Health in Post-Menopausal Women
Status: Enrolling
Updated:  12/31/1969
Univ of Nebraska Med Ctr
mi
from
Omaha, NE
Heartland Osteoporosis Prevention Study
Randomized Control Trial of Bone Loading Exercises Versus Risedronate on Bone Health in Post-Menopausal Women
Status: Enrolling
Updated: 12/31/1969
Univ of Nebraska Med Ctr
mi
from
Omaha, NE
Click here to add this to my saved trials
Prevention of Bone Loss After Acute SCI by Zoledronic Acid
Prevention of Bone Loss After Acute SCI by Zoledronic Acid: Durability, Effect on Bone Strength, and Use of Biomarkers to Guide Therapy
Status: Enrolling
Updated:  12/31/1969
Northwestern University Feinberg School of Medicine
mi
from
Chicago, IL
Prevention of Bone Loss After Acute SCI by Zoledronic Acid
Prevention of Bone Loss After Acute SCI by Zoledronic Acid: Durability, Effect on Bone Strength, and Use of Biomarkers to Guide Therapy
Status: Enrolling
Updated: 12/31/1969
Northwestern University Feinberg School of Medicine
mi
from
Chicago, IL
Click here to add this to my saved trials
Prevention of Bone Loss After Acute SCI by Zoledronic Acid
Prevention of Bone Loss After Acute SCI by Zoledronic Acid: Durability, Effect on Bone Strength, and Use of Biomarkers to Guide Therapy
Status: Enrolling
Updated:  12/31/1969
Rehabilitation Institute of Chicago
mi
from
Chicago, IL
Prevention of Bone Loss After Acute SCI by Zoledronic Acid
Prevention of Bone Loss After Acute SCI by Zoledronic Acid: Durability, Effect on Bone Strength, and Use of Biomarkers to Guide Therapy
Status: Enrolling
Updated: 12/31/1969
Rehabilitation Institute of Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
A Study of 2 Different Formulations of Blosozumab (LY2541546) in Post Menopausal Women
A Multiple-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of 2 Formulations of Blosozumab in Postmenopausal Women
Status: Enrolling
Updated:  12/31/1969
Covance Clinical Research Inc
mi
from
Evansville, IN
A Study of 2 Different Formulations of Blosozumab (LY2541546) in Post Menopausal Women
A Multiple-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of 2 Formulations of Blosozumab in Postmenopausal Women
Status: Enrolling
Updated: 12/31/1969
Covance Clinical Research Inc
mi
from
Evansville, IN
Click here to add this to my saved trials
A Study of 2 Different Formulations of Blosozumab (LY2541546) in Post Menopausal Women
A Multiple-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of 2 Formulations of Blosozumab in Postmenopausal Women
Status: Enrolling
Updated:  12/31/1969
Covance, Inc.
mi
from
Dallas, TX
A Study of 2 Different Formulations of Blosozumab (LY2541546) in Post Menopausal Women
A Multiple-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of 2 Formulations of Blosozumab in Postmenopausal Women
Status: Enrolling
Updated: 12/31/1969
Covance, Inc.
mi
from
Dallas, TX
Click here to add this to my saved trials
A Study of 2 Different Formulations of Blosozumab (LY2541546) in Post Menopausal Women
A Multiple-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of 2 Formulations of Blosozumab in Postmenopausal Women
Status: Enrolling
Updated:  12/31/1969
Covance, Inc.
mi
from
Daytona Beach, FL
A Study of 2 Different Formulations of Blosozumab (LY2541546) in Post Menopausal Women
A Multiple-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of 2 Formulations of Blosozumab in Postmenopausal Women
Status: Enrolling
Updated: 12/31/1969
Covance, Inc.
mi
from
Daytona Beach, FL
Click here to add this to my saved trials
Longitudinal Effects of Denosumab on Trabecular Bone Score and Femur Strength Index
Longitudinal Effects of Denosumab on Trabecular Bone Score and Femur Strength Index
Status: Enrolling
Updated:  12/31/1969
HealthEast Care System
mi
from
Saint Paul, MN
Longitudinal Effects of Denosumab on Trabecular Bone Score and Femur Strength Index
Longitudinal Effects of Denosumab on Trabecular Bone Score and Femur Strength Index
Status: Enrolling
Updated: 12/31/1969
HealthEast Care System
mi
from
Saint Paul, MN
Click here to add this to my saved trials
Dose Response and Receptor Selectivity of Beta-blocker Effects on Bone Metabolism
Dose Response and Receptor Selectivity of Beta-blocker Effects on Bone Metabolism
Status: Enrolling
Updated:  12/31/1969
Mayo Clinic Rochester
mi
from
Rochester, MN
Dose Response and Receptor Selectivity of Beta-blocker Effects on Bone Metabolism
Dose Response and Receptor Selectivity of Beta-blocker Effects on Bone Metabolism
Status: Enrolling
Updated: 12/31/1969
Mayo Clinic Rochester
mi
from
Rochester, MN
Click here to add this to my saved trials
Transdermal Estrogen in Older Premenopausal Women With Anorexia Nervosa
Transdermal Estrogen in Older Premenopausal Women With Anorexia Nervosa
Status: Enrolling
Updated:  12/31/1969
Massachusetts General Hospital
mi
from
Boston, MA
Transdermal Estrogen in Older Premenopausal Women With Anorexia Nervosa
Transdermal Estrogen in Older Premenopausal Women With Anorexia Nervosa
Status: Enrolling
Updated: 12/31/1969
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Analysis of Hypovitaminosis D and Osteopenia/Osteoporosis in Spinal Disease Patients Who Underwent a Spinal Fusion at Illinois Neurological Institute, Peoria, IL., a Retrospective Review From November 1, 2012 to October 31, 2014 and Prospective Pilot From July 1, 2015-June 30, 2016
Analysis of Hypovitaminosis D and Osteopenia/Osteoporosis in Spinal Disease Patients Who Underwent a Spinal Fusion at Illinois Neurological Institute, Peoria, IL., a Retrospective Review From November 1, 2012 to October 31, 2014 and Prospective Pilot From July 1, 2015-June 30, 2016
Status: Enrolling
Updated:  12/31/1969
OSF Saint Francis Medical Center
mi
from
Peoria, IL
Analysis of Hypovitaminosis D and Osteopenia/Osteoporosis in Spinal Disease Patients Who Underwent a Spinal Fusion at Illinois Neurological Institute, Peoria, IL., a Retrospective Review From November 1, 2012 to October 31, 2014 and Prospective Pilot From July 1, 2015-June 30, 2016
Analysis of Hypovitaminosis D and Osteopenia/Osteoporosis in Spinal Disease Patients Who Underwent a Spinal Fusion at Illinois Neurological Institute, Peoria, IL., a Retrospective Review From November 1, 2012 to October 31, 2014 and Prospective Pilot From July 1, 2015-June 30, 2016
Status: Enrolling
Updated: 12/31/1969
OSF Saint Francis Medical Center
mi
from
Peoria, IL
Click here to add this to my saved trials
Effect of Blueberries on Bone Turnover
Berries and Bones: The Effect of Polyphenolic Metabolites From Blueberries on Bone Turnover
Status: Enrolling
Updated:  12/31/1969
Department of Nutrition Science Purdue University
mi
from
West Lafayette, IN
Effect of Blueberries on Bone Turnover
Berries and Bones: The Effect of Polyphenolic Metabolites From Blueberries on Bone Turnover
Status: Enrolling
Updated: 12/31/1969
Department of Nutrition Science Purdue University
mi
from
West Lafayette, IN
Click here to add this to my saved trials
ACTIMMUNE in Intermediate Osteopetrosis
Open-label Early Phase 2 Study With a Single Arm of Interferon Gamma-1b Treatment of Osteopetrosis
Status: Enrolling
Updated:  12/31/1969
Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center
mi
from
Torrance, CA
ACTIMMUNE in Intermediate Osteopetrosis
Open-label Early Phase 2 Study With a Single Arm of Interferon Gamma-1b Treatment of Osteopetrosis
Status: Enrolling
Updated: 12/31/1969
Los Angeles Biomedical Research Institute at Harbor UCLA Medical Center
mi
from
Torrance, CA
Click here to add this to my saved trials
ACTIMMUNE in Intermediate Osteopetrosis
Open-label Early Phase 2 Study With a Single Arm of Interferon Gamma-1b Treatment of Osteopetrosis
Status: Enrolling
Updated:  12/31/1969
Univ of Minnesota
mi
from
Minneapolis, MN
ACTIMMUNE in Intermediate Osteopetrosis
Open-label Early Phase 2 Study With a Single Arm of Interferon Gamma-1b Treatment of Osteopetrosis
Status: Enrolling
Updated: 12/31/1969
Univ of Minnesota
mi
from
Minneapolis, MN
Click here to add this to my saved trials
A Direct-to-patient Intervention to Increase Rates of Osteoporosis Care
Activating Patients to Reduce OsteoPOrosiS
Status: Enrolling
Updated:  12/31/1969
University of Alabama at Birmingham
mi
from
Birmingham, AL
A Direct-to-patient Intervention to Increase Rates of Osteoporosis Care
Activating Patients to Reduce OsteoPOrosiS
Status: Enrolling
Updated: 12/31/1969
University of Alabama at Birmingham
mi
from
Birmingham, AL
Click here to add this to my saved trials
A Direct-to-patient Intervention to Increase Rates of Osteoporosis Care
Activating Patients to Reduce OsteoPOrosiS
Status: Enrolling
Updated:  12/31/1969
Cedars-Sinai Medical Center
mi
from
Los Angeles, CA
A Direct-to-patient Intervention to Increase Rates of Osteoporosis Care
Activating Patients to Reduce OsteoPOrosiS
Status: Enrolling
Updated: 12/31/1969
Cedars-Sinai Medical Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Direct-to-patient Intervention to Increase Rates of Osteoporosis Care
Activating Patients to Reduce OsteoPOrosiS
Status: Enrolling
Updated:  12/31/1969
University of Massachusetts Worcester
mi
from
Worcester, MA
A Direct-to-patient Intervention to Increase Rates of Osteoporosis Care
Activating Patients to Reduce OsteoPOrosiS
Status: Enrolling
Updated: 12/31/1969
University of Massachusetts Worcester
mi
from
Worcester, MA
Click here to add this to my saved trials
A Direct-to-patient Intervention to Increase Rates of Osteoporosis Care
Activating Patients to Reduce OsteoPOrosiS
Status: Enrolling
Updated:  12/31/1969
New York University
mi
from
New York, NY
A Direct-to-patient Intervention to Increase Rates of Osteoporosis Care
Activating Patients to Reduce OsteoPOrosiS
Status: Enrolling
Updated: 12/31/1969
New York University
mi
from
New York, NY
Click here to add this to my saved trials
A Direct-to-patient Intervention to Increase Rates of Osteoporosis Care
Activating Patients to Reduce OsteoPOrosiS
Status: Enrolling
Updated:  12/31/1969
Jewish Hospital of Cincinnati, Inc.
mi
from
Cincinnati, OH
A Direct-to-patient Intervention to Increase Rates of Osteoporosis Care
Activating Patients to Reduce OsteoPOrosiS
Status: Enrolling
Updated: 12/31/1969
Jewish Hospital of Cincinnati, Inc.
mi
from
Cincinnati, OH
Click here to add this to my saved trials
A Direct-to-patient Intervention to Increase Rates of Osteoporosis Care
Activating Patients to Reduce OsteoPOrosiS
Status: Enrolling
Updated:  12/31/1969
University of Pittsburgh
mi
from
Pittsburgh, PA
A Direct-to-patient Intervention to Increase Rates of Osteoporosis Care
Activating Patients to Reduce OsteoPOrosiS
Status: Enrolling
Updated: 12/31/1969
University of Pittsburgh
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
A Direct-to-patient Intervention to Increase Rates of Osteoporosis Care
Activating Patients to Reduce OsteoPOrosiS
Status: Enrolling
Updated:  12/31/1969
Group Health Research Institute
mi
from
Seattle, WA
A Direct-to-patient Intervention to Increase Rates of Osteoporosis Care
Activating Patients to Reduce OsteoPOrosiS
Status: Enrolling
Updated: 12/31/1969
Group Health Research Institute
mi
from
Seattle, WA
Click here to add this to my saved trials
12 Month Extension Study of the Effect of Teriparatide on Bone in People With Chronic Spinal Cord Injury (SCI)
12 Month Open-Label Extension Study of the Effect of Teriparatide on Bone in People With Chronic SCI
Status: Enrolling
Updated:  12/31/1969
Northwestern University Feinberg School of Medicine
mi
from
Chicago, IL
12 Month Extension Study of the Effect of Teriparatide on Bone in People With Chronic Spinal Cord Injury (SCI)
12 Month Open-Label Extension Study of the Effect of Teriparatide on Bone in People With Chronic SCI
Status: Enrolling
Updated: 12/31/1969
Northwestern University Feinberg School of Medicine
mi
from
Chicago, IL
Click here to add this to my saved trials
Effect of Alendronate on Bone in People With Chronic Spinal Cord Injury (SCI) Previously Treated With Teriparatide
12 Month Open-Label Extension Study of the Effect of Alendronate on Bone in People With Chronic SCI Previously Treated With Teriparatide
Status: Enrolling
Updated:  12/31/1969
Northwestern University Feinberg School of Medicine
mi
from
Chicago, IL
Effect of Alendronate on Bone in People With Chronic Spinal Cord Injury (SCI) Previously Treated With Teriparatide
12 Month Open-Label Extension Study of the Effect of Alendronate on Bone in People With Chronic SCI Previously Treated With Teriparatide
Status: Enrolling
Updated: 12/31/1969
Northwestern University Feinberg School of Medicine
mi
from
Chicago, IL
Click here to add this to my saved trials
Persistence With Prolia® (Denosumab) in Postmenopausal Women With Osteoporosis
Prospective Observational Study to Evaluate Persistence With Prolia® (Denosumab) in Postmenopausal Women With Osteoporosis in Routine Clinical Practice
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Birmingham, AL
Persistence With Prolia® (Denosumab) in Postmenopausal Women With Osteoporosis
Prospective Observational Study to Evaluate Persistence With Prolia® (Denosumab) in Postmenopausal Women With Osteoporosis in Routine Clinical Practice
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Birmingham, AL
Click here to add this to my saved trials
Persistence With Prolia® (Denosumab) in Postmenopausal Women With Osteoporosis
Prospective Observational Study to Evaluate Persistence With Prolia® (Denosumab) in Postmenopausal Women With Osteoporosis in Routine Clinical Practice
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Chandler, AZ
Persistence With Prolia® (Denosumab) in Postmenopausal Women With Osteoporosis
Prospective Observational Study to Evaluate Persistence With Prolia® (Denosumab) in Postmenopausal Women With Osteoporosis in Routine Clinical Practice
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Chandler, AZ
Click here to add this to my saved trials
Persistence With Prolia® (Denosumab) in Postmenopausal Women With Osteoporosis
Prospective Observational Study to Evaluate Persistence With Prolia® (Denosumab) in Postmenopausal Women With Osteoporosis in Routine Clinical Practice
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Peoria, AZ
Persistence With Prolia® (Denosumab) in Postmenopausal Women With Osteoporosis
Prospective Observational Study to Evaluate Persistence With Prolia® (Denosumab) in Postmenopausal Women With Osteoporosis in Routine Clinical Practice
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Peoria, AZ
Click here to add this to my saved trials
Persistence With Prolia® (Denosumab) in Postmenopausal Women With Osteoporosis
Prospective Observational Study to Evaluate Persistence With Prolia® (Denosumab) in Postmenopausal Women With Osteoporosis in Routine Clinical Practice
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Phoenix, AZ
Persistence With Prolia® (Denosumab) in Postmenopausal Women With Osteoporosis
Prospective Observational Study to Evaluate Persistence With Prolia® (Denosumab) in Postmenopausal Women With Osteoporosis in Routine Clinical Practice
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Persistence With Prolia® (Denosumab) in Postmenopausal Women With Osteoporosis
Prospective Observational Study to Evaluate Persistence With Prolia® (Denosumab) in Postmenopausal Women With Osteoporosis in Routine Clinical Practice
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Hemet, CA
Persistence With Prolia® (Denosumab) in Postmenopausal Women With Osteoporosis
Prospective Observational Study to Evaluate Persistence With Prolia® (Denosumab) in Postmenopausal Women With Osteoporosis in Routine Clinical Practice
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Hemet, CA
Click here to add this to my saved trials
Persistence With Prolia® (Denosumab) in Postmenopausal Women With Osteoporosis
Prospective Observational Study to Evaluate Persistence With Prolia® (Denosumab) in Postmenopausal Women With Osteoporosis in Routine Clinical Practice
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Laguna Hills, CA
Persistence With Prolia® (Denosumab) in Postmenopausal Women With Osteoporosis
Prospective Observational Study to Evaluate Persistence With Prolia® (Denosumab) in Postmenopausal Women With Osteoporosis in Routine Clinical Practice
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Laguna Hills, CA
Click here to add this to my saved trials
Persistence With Prolia® (Denosumab) in Postmenopausal Women With Osteoporosis
Prospective Observational Study to Evaluate Persistence With Prolia® (Denosumab) in Postmenopausal Women With Osteoporosis in Routine Clinical Practice
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Los Angeles, CA
Persistence With Prolia® (Denosumab) in Postmenopausal Women With Osteoporosis
Prospective Observational Study to Evaluate Persistence With Prolia® (Denosumab) in Postmenopausal Women With Osteoporosis in Routine Clinical Practice
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Los Angeles, CA
Click here to add this to my saved trials